Evidence map›Paper›PMID 31572794›Full record

ArticleBioengineering & translational medicine2019

Facilitating plasmid nuclear delivery by interfering with the selective nuclear pore barrier.

Ihab Azzam, Ivan Liashkovich, Isabelle Luchtefeld, Ivan U Kouzel, Victor Shahin

Abstract read
In one paragraph

Article in Bioengineering & translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ihab AzzamInstitute of Physiology II University of Münster Münster Germany.
Ivan LiashkovichInstitute of Physiology II University of Münster Münster Germany.
Isabelle LuchtefeldInstitute of Physiology II University of Münster Münster Germany.
Ivan U KouzelInstitute of Hygiene University of Münster Münster Germany.
Victor ShahinInstitute of Physiology II University of Münster Münster Germany.ORCID https://orcid.org/0000-0003-2710-6473

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear pore complexes (NPCs) are sophisticated transporters assembled from diverse proteins termed nucleoporins (Nups). They control all nucleocytoplasmic transport and form a stringent barrier between the cytosol and the nucleus. While selective receptor-mediated transport enables translocation of macromolecules up to striking sizes approaching megadalton-scale, the upper cutoff for diffusion is at 40 kDa. Raising the cutoff is of particular importance for nuclear delivery of therapeutic nanoparticles, for example, gene and chemotherapy. In this work, we set out to present compounds capable of raising the cutoff to an extent enabling nuclear delivery of 6 kbp pDNA (150 kDa) in cultured human vascular endothelial cells. Of all tested compounds one is singled out, 1,6-hexanediol (1,6-HD). Our observations reveal that 1,6-HD facilitates nuclear delivery of pDNA in up to 10-20% of the tested cells, compared to no delivery at all in control conditions. It acts by interfering with bonds between Nups that occupy the NPC channel and confer transport selectivity. It also largely maintains cell viability even at high concentrations. We envisage that 1,6-HD may serve as a lead substance and usher in the design of potent new strategies to increase nuclear delivery of therapeutic nanoparticles.

Indexed as

nanomedicinenanoparticlesnuclear porespharmacologyphysiology

Identifiers

PMID31572794
PMCPMC6764801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.